AU2006248825B2 - Fluorene derivatives, composition containing said derivatives and the use thereof - Google Patents
Fluorene derivatives, composition containing said derivatives and the use thereof Download PDFInfo
- Publication number
- AU2006248825B2 AU2006248825B2 AU2006248825A AU2006248825A AU2006248825B2 AU 2006248825 B2 AU2006248825 B2 AU 2006248825B2 AU 2006248825 A AU2006248825 A AU 2006248825A AU 2006248825 A AU2006248825 A AU 2006248825A AU 2006248825 B2 AU2006248825 B2 AU 2006248825B2
- Authority
- AU
- Australia
- Prior art keywords
- fluoren
- imidazo
- pyridin
- carboxylic acid
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0505037 | 2005-05-19 | ||
FR0505037A FR2885904B1 (fr) | 2005-05-19 | 2005-05-19 | Nouveaux derives du fluorene, compositions les contenant et utilisation |
PCT/FR2006/001137 WO2006123061A2 (fr) | 2005-05-19 | 2006-05-19 | Derives du fluorene, compositions les contenant et utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2006248825A1 AU2006248825A1 (en) | 2006-11-23 |
AU2006248825B2 true AU2006248825B2 (en) | 2012-02-23 |
Family
ID=36036699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006248825A Ceased AU2006248825B2 (en) | 2005-05-19 | 2006-05-19 | Fluorene derivatives, composition containing said derivatives and the use thereof |
Country Status (31)
Country | Link |
---|---|
US (1) | US7674795B2 (pt) |
EP (1) | EP1888579B1 (pt) |
JP (1) | JP4964874B2 (pt) |
KR (1) | KR101288696B1 (pt) |
CN (1) | CN101203518B (pt) |
AR (1) | AR054125A1 (pt) |
AT (1) | ATE518859T1 (pt) |
AU (1) | AU2006248825B2 (pt) |
BR (1) | BRPI0611424A2 (pt) |
CA (1) | CA2608378C (pt) |
CR (1) | CR9515A (pt) |
DO (1) | DOP2006000112A (pt) |
EA (1) | EA019027B1 (pt) |
FR (1) | FR2885904B1 (pt) |
GT (1) | GT200600206A (pt) |
HN (1) | HN2006018410A (pt) |
IL (1) | IL187163A (pt) |
JO (1) | JO2753B1 (pt) |
MA (1) | MA29493B1 (pt) |
MX (1) | MX2007014443A (pt) |
MY (1) | MY149037A (pt) |
NO (1) | NO20076460L (pt) |
NZ (1) | NZ563239A (pt) |
PA (1) | PA8675701A1 (pt) |
PE (1) | PE20061367A1 (pt) |
TN (1) | TNSN07389A1 (pt) |
TW (1) | TWI386406B (pt) |
UA (1) | UA93203C2 (pt) |
UY (1) | UY29549A1 (pt) |
WO (1) | WO2006123061A2 (pt) |
ZA (1) | ZA200709856B (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008011919A (es) | 2006-03-16 | 2008-11-28 | Renovis Inc | Compuestos de bicicloheteroarilo como moduladores de p2x7 y usos de los mismos. |
FR2907453B1 (fr) * | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
JP5270571B2 (ja) * | 2007-11-22 | 2013-08-21 | 出光興産株式会社 | 有機el素子 |
AU2009233324B2 (en) * | 2008-03-31 | 2015-01-22 | Council Of Scientific & Industrial Research | Donor-acceptor fluorene scaffolds : a process and uses thereof |
GB0809314D0 (en) * | 2008-05-22 | 2008-07-02 | Summit Corp Plc | Compounds for treating muscular dystrophy |
WO2009158118A2 (en) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
FR2932484B1 (fr) * | 2008-06-16 | 2010-06-18 | Sanofi Aventis | Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation |
RU2015107733A (ru) * | 2008-07-02 | 2015-06-27 | Бритиш Коламбиа Кэнсер Эйдженси Бранч | Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения |
AR074797A1 (es) | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
CA2786319C (en) | 2010-01-06 | 2019-03-12 | British Columbia Cancer Agency Branch | Bisphenol derivatives and their use as androgen receptor activity modulators |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
WO2012145330A1 (en) * | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Fluorene-9-bisphenol compounds and methods for their use |
CN102442973A (zh) * | 2011-09-22 | 2012-05-09 | 华东理工大学 | 催化氧化伯醇闭环合成苯并咪唑和苯并噻唑化合物的方法 |
KR102020083B1 (ko) * | 2012-01-31 | 2019-09-09 | 캠브리지 디스플레이 테크놀로지 리미티드 | 중합체 |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
US9533002B2 (en) | 2012-05-25 | 2017-01-03 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β |
PL2975028T3 (pl) | 2013-03-15 | 2018-10-31 | Japan Tobacco, Inc. | Związek pirazoloamidowy i jego zastosowania medyczne |
CN105358522A (zh) | 2013-05-10 | 2016-02-24 | 不列颠哥伦比亚癌症局分支机构 | 雄激素受体调节剂的酯衍生物及其使用方法 |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
EP3044197B1 (en) | 2013-09-09 | 2018-11-07 | British Columbia Cancer Agency Branch | Halogenated compounds for cancer imaging and treatment and methods for their use |
KR102280686B1 (ko) | 2014-02-11 | 2021-07-22 | 삼성전자주식회사 | 카바졸계 화합물 및 이를 포함한 유기 발광 소자 |
WO2015160845A2 (en) * | 2014-04-14 | 2015-10-22 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
WO2015188198A2 (en) | 2014-06-06 | 2015-12-10 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
AU2015357489A1 (en) | 2014-12-05 | 2017-07-06 | Case Western Reserve University | Compositions and methods of modulating S-nitrosylation |
US11426386B2 (en) | 2014-12-05 | 2022-08-30 | Case Western Reserve University | Compositions and methods of modulating S-nitrosylation |
AU2016206412B2 (en) | 2015-01-13 | 2020-10-08 | British Columbia Cancer Agency Branch | Heterocyclic compounds for cancer imaging and treatment and methods for their use |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
CN108136044B (zh) * | 2015-06-04 | 2021-08-10 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
EP3492452B1 (en) | 2016-07-29 | 2022-08-31 | Japan Tobacco Inc. | Production method for pyrazole-amide compound |
CA3076889A1 (en) | 2017-09-25 | 2019-03-28 | Case Western Reserve University | Compositions and methods of reducing serum cholesterol and pcsk9 |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
US11931339B2 (en) | 2018-06-25 | 2024-03-19 | Case Western Reserve University | Compositions and methods for treating tissue injury |
EP3852750A4 (en) * | 2018-09-21 | 2022-05-11 | Case Western Reserve University | ALDOKETO REDUCTAE INHIBITORS AND THEIR USES |
BR112021007222A8 (pt) | 2018-10-18 | 2022-11-22 | Provincial Health Services Authority | Moduladores de receptor de androgênio e métodos para seu uso |
CN109574917B (zh) * | 2018-12-03 | 2020-12-08 | 武汉尚赛光电科技有限公司 | 一种芴酮衍生物及其制备和应用 |
SG11202106304RA (en) | 2018-12-31 | 2021-07-29 | Biomea Fusion Llc | Irreversible inhibitors of menin-mll interaction |
TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
CN110981795B (zh) * | 2019-12-18 | 2021-02-12 | 武汉世纪久海检测技术有限公司 | 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法 |
WO2021212032A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6015796A (en) * | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
AU8645401A (en) * | 2000-08-14 | 2002-02-25 | Ortho Mcneil Pharm Inc | Substituted pyrazoles |
ATE374753T1 (de) * | 2001-12-21 | 2007-10-15 | Vernalis Cambridge Ltd | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
BR0317525A (pt) * | 2002-12-20 | 2005-11-16 | Pharmacia Corp | Compostos pirazol acìclico, composição terapêutica e farmacêutica, kit, bem como respectivos usos |
US7160885B2 (en) * | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
EA009919B1 (ru) | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
ES2432747T3 (es) | 2003-06-27 | 2013-12-05 | Kyowa Hakko Kirin Co., Ltd. | Inhibidores de proteínas de la familia HSP90 |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
KR101139314B1 (ko) | 2003-08-29 | 2012-04-26 | 베르날리스(캠브리지)리미티드 | 피리미도티오펜 화합물 |
GB0323810D0 (en) * | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
US7538241B2 (en) * | 2003-12-26 | 2009-05-26 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90 family protein inhibitors |
FR2884252B1 (fr) * | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
-
2005
- 2005-05-19 FR FR0505037A patent/FR2885904B1/fr not_active Expired - Fee Related
-
2006
- 2006-05-12 DO DO2006000112A patent/DOP2006000112A/es unknown
- 2006-05-14 JO JO2006135A patent/JO2753B1/en active
- 2006-05-17 HN HN2006018410A patent/HN2006018410A/es unknown
- 2006-05-17 AR ARP060101980A patent/AR054125A1/es not_active Application Discontinuation
- 2006-05-17 PE PE2006000520A patent/PE20061367A1/es not_active Application Discontinuation
- 2006-05-18 MY MYPI20062304A patent/MY149037A/en unknown
- 2006-05-18 GT GT200600206A patent/GT200600206A/es unknown
- 2006-05-18 PA PA20068675701A patent/PA8675701A1/es unknown
- 2006-05-19 NZ NZ563239A patent/NZ563239A/en not_active IP Right Cessation
- 2006-05-19 UA UAA200714230A patent/UA93203C2/ru unknown
- 2006-05-19 CA CA2608378A patent/CA2608378C/fr not_active Expired - Fee Related
- 2006-05-19 CN CN2006800219737A patent/CN101203518B/zh not_active Expired - Fee Related
- 2006-05-19 BR BRPI0611424-5A patent/BRPI0611424A2/pt not_active IP Right Cessation
- 2006-05-19 AT AT06755509T patent/ATE518859T1/de not_active IP Right Cessation
- 2006-05-19 MX MX2007014443A patent/MX2007014443A/es active IP Right Grant
- 2006-05-19 AU AU2006248825A patent/AU2006248825B2/en not_active Ceased
- 2006-05-19 TW TW095117762A patent/TWI386406B/zh not_active IP Right Cessation
- 2006-05-19 UY UY29549A patent/UY29549A1/es unknown
- 2006-05-19 EA EA200702531A patent/EA019027B1/ru unknown
- 2006-05-19 EP EP06755509A patent/EP1888579B1/fr active Active
- 2006-05-19 WO PCT/FR2006/001137 patent/WO2006123061A2/fr not_active Application Discontinuation
- 2006-05-19 KR KR1020077029644A patent/KR101288696B1/ko not_active IP Right Cessation
- 2006-05-19 JP JP2008511754A patent/JP4964874B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-18 TN TNP2007000389A patent/TNSN07389A1/en unknown
- 2007-11-05 IL IL187163A patent/IL187163A/en not_active IP Right Cessation
- 2007-11-13 CR CR9515A patent/CR9515A/es unknown
- 2007-11-14 US US11/939,735 patent/US7674795B2/en active Active
- 2007-11-15 ZA ZA2007/09856A patent/ZA200709856B/en unknown
- 2007-11-29 MA MA30431A patent/MA29493B1/fr unknown
- 2007-12-14 NO NO20076460A patent/NO20076460L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006248825B2 (en) | Fluorene derivatives, composition containing said derivatives and the use thereof | |
AU2006223070B2 (en) | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | |
AU2010320963B2 (en) | Novel heterocyclic acrylamides and their use as pharmaceuticals | |
CA2661842C (en) | Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators | |
AU2009281822B2 (en) | cMET inhibitors | |
AU2006273692B2 (en) | 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
CA2410393A1 (en) | 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors | |
AU2004261667A1 (en) | Bicyclic imidazol derivatives against Flaviviridae | |
AU2009232121A1 (en) | Novel HSP90 inhibitory carbazole derivatives, compositions containing same, and use thereof | |
CZ20031676A3 (en) | Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors | |
Khoje et al. | Synthesis and antimycobacterial activities of non-purine analogs of 6-aryl-9-benzylpurines: Imidazopyridines, pyrrolopyridines, benzimidazoles, and indoles | |
US20120010241A1 (en) | Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof | |
EP3558321B1 (en) | Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases | |
FR2907453A1 (fr) | Nouveaux derives du fluorene,compositions les contenant et utilisation | |
AU2022406595A1 (en) | Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof | |
Amr et al. | Antianexiety activity of pyridine derivatives synthesized from 2-chloro-6-hydrazino-isonicotinic acid hydrazide | |
AU2022425324A1 (en) | Tricyclic derivative inhibitor, preparation method therefor, and application thereof | |
CN116375683A (zh) | 二氮唑类衍生物抑制剂、其制备方法和应用 | |
AU2011244844A1 (en) | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | |
CA2759162A1 (en) | Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |